DiaMedica Therapeutics (DMAC) Income from Continuing Operations (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Income from Continuing Operations for 9 consecutive years, with -$10.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations fell 31.69% year-over-year to -$10.1 million; the trailing twelve-month figure through Jun 2026 stood at -$33.0 million (down 27.22% YoY), and the FY2025 full-year result was -$28.2 million, down 35.68% from the prior year.
• Income from Continuing Operations fell to -$10.1 million in Q2 2026 per DMAC's latest filing, from -$10.0 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at -$3.1 million in Q3 2022 and bottomed at -$10.1 million in Q2 2026.
• Historically, Income from Continuing Operations has averaged -$5.7 million across 5 years, with a median of -$5.1 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations climbed 17.73% in 2024, then tumbled 50.4% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$3.8 million in 2022, then sank by 36.35% to -$5.2 million in 2023, then climbed by 17.73% to -$4.2 million in 2024, then gained by 1.51% to -$4.2 million in 2025, then tumbled by 142.44% to -$10.1 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$10.1 million, -$10.0 million, and -$4.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.